1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Hepatic Encephalopathy Therapeutics Market
2.3. Global Hepatic Encephalopathy Therapeutics Market, By Drug Class, 2025 (US$ Million)
2.4. Global Hepatic Encephalopathy Therapeutics Market, By Diagnosis, 2025 (US$ Million)
2.5. Global Hepatic Encephalopathy Therapeutics Market, By Route of Administration, 2025 (US$ Million)
2.6. Global Hepatic Encephalopathy Therapeutics Market, By Distribution Channel, 2025 (US$ Million)
2.7. Global Hepatic Encephalopathy Therapeutics Market, By Geography, 2025 (US$ Million)
2.8. Attractive Investment Proposition by Geography, 2025
3. Hepatic Encephalopathy Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Hepatic Encephalopathy Therapeutics Market Vendors
3.2. Strategies Adopted by Hepatic Encephalopathy Therapeutics Market Vendors
4. Hepatic Encephalopathy Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Hepatic Encephalopathy Therapeutics Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Antibiotics
5.3.2. Laxatives
5.3.3. L-ornithine
5.3.4. L-aspartate
6. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Blood Tests
6.3.2. CT Scan
6.3.3. Liver Functioning Tests
7. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2025 Versus 2034
7.3. Market Segmentation
7.3.1. Oral
7.3.2. Injectable
7.3.3. Intravenous
7.3.4. Others
8. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2025 Versus 2034
8.3. Market Segmentation
8.3.1. Hospital Pharmacy
8.3.2. Online Pharmacy
8.3.3. Retail Pharmacy
9. North America Hepatic Encephalopathy Therapeutics Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
9.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
9.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
9.6. Hepatic Encephalopathy Therapeutics Market: By Region, 2024-2034, USD (Million)
9.6.1.North America
9.6.1.1. U.S.
9.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9.6.1.1.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
9.6.1.1.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
9.6.1.1.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
9.6.1.2. Canada
9.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9.6.1.2.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
9.6.1.2.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
9.6.1.2.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
9.6.1.3. Rest of North America
9.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9.6.1.3.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
9.6.1.3.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
9.6.1.3.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
10. UK and European Union Hepatic Encephalopathy Therapeutics Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
10.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
10.6. Hepatic Encephalopathy Therapeutics Market: By Region, 2024-2034, USD (Million)
10.6.1.UK and European Union
10.6.1.1. UK
10.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.6.1.1.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
10.6.1.1.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.6.1.1.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
10.6.1.2. Germany
10.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.6.1.2.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
10.6.1.2.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.6.1.2.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
10.6.1.3. Spain
10.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.6.1.3.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
10.6.1.3.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.6.1.3.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
10.6.1.4. Italy
10.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.6.1.4.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
10.6.1.4.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.6.1.4.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
10.6.1.5. France
10.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.6.1.5.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
10.6.1.5.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.6.1.5.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
10.6.1.6. Rest of Europe
10.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.6.1.6.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
10.6.1.6.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
10.6.1.6.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
11. Asia Pacific Hepatic Encephalopathy Therapeutics Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
11.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
11.6. Hepatic Encephalopathy Therapeutics Market: By Region, 2024-2034, USD (Million)
11.6.1.Asia Pacific
11.6.1.1. China
11.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11.6.1.1.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
11.6.1.1.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.6.1.1.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
11.6.1.2. Japan
11.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11.6.1.2.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
11.6.1.2.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.6.1.2.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
11.6.1.3. India
11.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11.6.1.3.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
11.6.1.3.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.6.1.3.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
11.6.1.4. Australia
11.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11.6.1.4.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
11.6.1.4.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.6.1.4.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
11.6.1.5. South Korea
11.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11.6.1.5.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
11.6.1.5.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.6.1.5.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
11.6.1.6. Rest of Asia Pacific
11.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11.6.1.6.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
11.6.1.6.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
11.6.1.6.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
12. Latin America Hepatic Encephalopathy Therapeutics Market, 2024-2034, USD (Million)
12.1. Market Overview
12.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
12.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
12.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
12.6. Hepatic Encephalopathy Therapeutics Market: By Region, 2024-2034, USD (Million)
12.6.1.Latin America
12.6.1.1. Brazil
12.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
12.6.1.1.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
12.6.1.1.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.6.1.1.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
12.6.1.2. Mexico
12.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
12.6.1.2.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
12.6.1.2.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.6.1.2.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
12.6.1.3. Rest of Latin America
12.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
12.6.1.3.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
12.6.1.3.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
12.6.1.3.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
13. Middle East and Africa Hepatic Encephalopathy Therapeutics Market, 2024-2034, USD (Million)
13.1. Market Overview
13.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
13.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
13.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
13.6. Hepatic Encephalopathy Therapeutics Market: By Region, 2024-2034, USD (Million)
13.6.1.Middle East and Africa
13.6.1.1. GCC
13.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
13.6.1.1.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
13.6.1.1.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.6.1.1.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
13.6.1.2. Africa
13.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
13.6.1.2.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
13.6.1.2.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.6.1.2.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
13.6.1.3. Rest of Middle East and Africa
13.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
13.6.1.3.2. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2024-2034, USD (Million)
13.6.1.3.3. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2024-2034, USD (Million)
13.6.1.3.4. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2024-2034, USD (Million)
14. Company Profile
14.1. Mallinckrodt Pharmaceuticals (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
14.2. Salix Pharmaceuticals
14.3. GlaxoSmithKline plc.
14.4. Pfizer Inc.
14.5. ASKA Pharmaceutical Co., Ltd.
14.6. Bausch Health
14.7. Johnson & Johnson Services, Inc.
14.8. Janssen Global Services
14.9. Takeda Pharmaceutical Company Limited, Merck & Co., Inc.
14.10. Others
